Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies

por Brada, M, Judson, I, Beale, P, Moore, S, Reidenberg, P, Statkevich, P, Dugan, M, Batra, V, Cutler, D
Publicado 1999

Phase I study of temozolomide in paediatric patients with advanced cancer. United Kingdom Children's Cancer Study Group.

por Estlin, E. J., Lashford, L., Ablett, S., Price, L., Gowing, R., Gholkar, A., Kohler, J., Lewis, I. J., Morland, B., Pinkerton, C. R., Stevens, M. C., Mott, M., Stevens, R., Newell, D. R., Walker, D., Dicks-Mireaux, C., McDowell, H., Reidenberg, P., Statkevich, P., Marco, A., Batra, V., Dugan, M., Pearson, A. D.
Publicado 1998